Page last updated: 2024-12-07

trisodium 3-hydroxy-4-((2z)-2-(2-oxo-4-sulfonatonaphthalen-1-ylidene)hydrazinyl)naphthalene-2,7-disulfonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trisodium 3-hydroxy-4-((2Z)-2-(2-oxo-4-sulfonatonaphthalen-1-ylidene)hydrazinyl)naphthalene-2,7-disulfonate: a metal indicator for calcium and a colorimetric reagent for alkaline earth metal ions used for a colorimetric assay of the loop-mediated isothermal amplification reaction reaction [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID113232
MeSH IDM0535217

Synonyms (28)

Synonym
hydroxy naphthol blue
1,1'-azonaphthalene, 2,2'-dihydroxy-3,3',6-trisulfonic acid-, trisodium salt
63451-35-4
hydroxynaphthol blue
trisodium 3-hydroxy-4-[2-(2-oxo-4-sulfonato-1-naphthalenylidene)hydrazinyl]naphthalene-2,7-disulfonate
A834389
trisodium 3-oxidanyl-4-[2-(2-oxidanylidene-4-sulfonato-naphthalen-1-ylidene)hydrazinyl]naphthalene-2,7-disulfonate
trisodium 3-hydroxy-4-((2z)-2-(2-oxo-4-sulfonatonaphthalen-1-ylidene)hydrazinyl)naphthalene-2,7-disulfonate
unii-vg5skf7s6c
2,7-naphthalenedisulfonic acid, 3-hydroxy-4-((2-hydroxy-4-sulfo-1-naphthalenyl)azo)-, trisodium salt
einecs 264-197-7
vg5skf7s6c ,
trisodium 3-hydroxy-4-((2-hydroxy-4-sulphonato-1-naphthyl)azo)naphthalene-2,7-disulphonate
2,7-naphthalenedisulfonic acid, 3-hydroxy-4-(2-(2-hydroxy-4-sulfo-1-naphthalenyl)diazenyl)-, sodium salt (1:3)
FT-0627137
2,7-naphthalenedisulfonic acid, 3-hydroxy-4-[(2-hydroxy-4-sulfo-1-naphthalenyl)azo]-, trisodium salt
mfcd00036393
DTXSID8069852
2,7-naphthalenedisulfonicacid,3-hydroxy-4-[2-(2-hydroxy-4-sulfo-1-naphthalenyl)diazenyl]-,sodium salt(1:3)
trisodium;3-hydroxy-4-[(2-hydroxy-4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2,7-disulfonate
sodium (e)-3-hydroxy-4-((2-hydroxy-4-sulfonatonaphthalen-1-yl)diazenyl)naphthalene-2,7-disulfonate
2,7-naphthalenedisulfonic acid,3-hydroxy-4-[(2-hydroxy-4-sulfo-1-naphthalenyl)azo]-, trisodium salt
sodium 3-hydroxy-4-((2-hydroxy-4-sulfonatonaphthalen-1-yl)diazenyl)naphthalene-2,7-disulfonate
1260907-08-1
2,7-naphthalenedisulfonic acid, 3-hydroxy-4-[2-(2-hydroxy-4-sulfo-1-naphthalenyl)diazenyl]-, sodium salt (1:3)
sodium (e)-3-hydroxy-4-[(2-hydroxy-4-sulfonato-1-naphthyl)diazenyl]naphthalene-2,7-disulfonate
SY274079
1-(2-hydroxy-4-sulfo-1-naphthylazo)-2-naphthol-3

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, the uracil-DNA glycosylase (UDG)-supplemented cross-priming amplification (UCPA) combined with a colorimetric detection method using the hydroxynaphthol blue (HNB) and lateral flow dipstick (LFD) for detection of SDDV was developed."( Development of cross-priming amplification (CPA) combined with colorimetric and lateral flow dipstick visualization for scale drop disease virus (SDDV) detection.
Chaivisuthangkura, P; Longyant, S; Prasitporn, T; Senapin, S; Vaniksampanna, A, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.04)29.6817
2010's36 (73.47)24.3611
2020's12 (24.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.57 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index5.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]